Foghorn Therapeutics Inc. FHTX
- selective EP300 degrader — Multiple Myeloma Preclinical
- selective EP300 degrader — Diffuse Large B-Cell Lymphoma Preclinical
EP300 (1 companies · 2 programs)
Companies with an active program directed at EP300.
Companies with an active program directed at EP300.